Canine TNF-alpha Antibody Summary
Val77-Leu233
Accession # P51742
Applications
Canine TNF-alpha Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Cytotoxicity Induced by TNF‑ alpha and Neutralization by Canine TNF‑ alpha Antibody. Recombinant Canine TNF-a (Catalog # 1507-CT) induces cytotoxicity in the the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Cytotoxicity elicited by Recombinant Canine TNF-a (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Canine TNF-a Monoclonal Antibody (Catalog # MAB1507). The ND50 is typically 1.25-5.0 µg/mL in the presence of the metabolic inhibitor actinomycin D (1 µg/mL).
TNF‑ alpha in Canine PBMCs. TNF-a was detected in immersion fixed canine peripheral blood mononuclear cells (PBMCs) untreated or treated with calcium ionomycin and PMA using Mouse Anti-Canine TNF-a Monoclonal Antibody (Catalog # MAB1507) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cell secretion. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: TNF-alpha
Tumor necrosis factor alpha (TNF-alpha ), also known as cachectin, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, apoptosis, and immune system development. TNF-alpha is produced by a wide variety of immune and epithelial cell types (1, 2). Canine TNF-alpha consisits of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 177 aa extracellular domain (ECD) (3). Within the ECD, canine TNF-alpha shares
84‑94% aa sequence identity with equine, feline, human, porcine, and rhesus and 69-77% with bovine, cotton rat, mouse, and rat with TNF-alpha. The 26 kDa type 2 transmembrane protein is assembled intracellularly to form a noncovalently linked homotrimer (4). Ligation of this complex induces reverse signaling that promotes lymphocyte co-stimulation but diminishes monocyte responsiveness (5). Cleavage of membrane bound TNF-alpha by TACE/ADAM17 releases a 55 kDa soluble trimeric form of TNF-alpha (6, 7). TNF-alpha trimers bind the ubiquitous TNF RI and the hematopoietic cell-restricted TNF RII, both of which are also expressed as homotrimers (1, 8). TNF-alpha regulates lymphoid tissue development through control of apoptosis (2). It also promotes inflammatory responses by inducing the activation of vascular endothelial cells and macrophages (2). TNF-alpha is a key cytokine in the development of several inflammatory disorders (9). It contributes to the development of type 2 diabetes through its effects on insulin resistance and fatty acid metabolism (10, 11).
- Idriss, H.T. and J.H. Naismith (2000) Microsc. Res. Tech. 50:184.
- Hehlgans, T. and K. Pfeffer (2005) Immunology 115:1.
- Zucker, K. et al. (1994) Lymphokine Cytokine Res. 13:191.
- Tang, P. et al. (1996) Biochemistry 35:8216.
- Eissner G. et al. (2004) Cytokine Growth Factor Rev. 15:353.
- Black, R.A. et al. (1997) Nature 385:729.
- Moss, M.L. et al. (1997) Nature 385:733.
- Loetscher, H. et al. (1991) J. Biol. Chem. 266:18324.
- Clark, I.A. (2007) Cytokine Growth Factor Rev. 18:335.
- Romanatto, T. et al. (2007) Peptides 28:1050.
- Hector, J. et al. (2007) Horm. Metab. Res. 39:250.
Product Datasheets
Citations for Canine TNF-alpha Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
3
Citations: Showing 1 - 3
Filter your results:
Filter by:
-
Phase I and II Clinical Trial Comparing the LBSap, Leishmune�, and Leish-Tec� Vaccines against Canine Visceral Leishmaniasis
Authors: RDO Aguiar-Soa, BM Roatt, FAS Mathias, LES Reis, JMO Cardoso, RCF Brito, HG Ker, R Corrêa-Oli, RC Giunchetti, AB Reis
Vaccines (Basel), 2020-11-17;8(4):.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Capture -
A Vaccine Therapy for Canine Visceral Leishmaniasis Promoted Significant Improvement of Clinical and Immune Status with Reduction in Parasite Burden
Authors: BM Roatt, RD Aguiar-Soa, LE Reis, JM Cardoso, FA Mathias, RC de Brito, SM da Silva, NF Gontijo, SA Ferreira, JG Valenzuela, R Corrêa-Oli, RC Giunchetti, AB Reis
Front Immunol, 2017-03-07;8(0):217.
Species: Canine
Sample Types: Cell Culture Supernates
Applications: ELISA Development (Capture) -
Expression of Toll-like receptors 2 and 9 in cells of dog jejunum and colon naturally infected with Leishmania infantum.
Authors: Figueiredo M, Amorim I, Pinto A, Barbosa V, Pinheiro L, Deoti B, Faria A, Tafuri W
BMC Immunol, 2013-05-14;14(0):22.
Species: Canine
Sample Types: Tissue Homogenates
Applications: ELISA Development
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Canine TNF-alpha Antibody
There are currently no reviews for this product. Be the first to review Canine TNF-alpha Antibody and earn rewards!
Have you used Canine TNF-alpha Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image